Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Aghajanian C, Samuelson MI, Lankes HA, Soslow RA, Leslie KK. Thiel KW, et al. Among authors: lankes ha. J Clin Oncol. 2022 Oct 1;40(28):3289-3300. doi: 10.1200/JCO.21.02506. Epub 2022 Jun 3. J Clin Oncol. 2022. PMID: 35658479 Free PMC article. Clinical Trial.
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Garcia AA, Sill MW, Lankes HA, Godwin AK, Mannel RS, Armstrong DK, Carolla RL, Liepman MK, Spirtos NM, Fischer EG, Leslie KK. Garcia AA, et al. Among authors: lankes ha. Gynecol Oncol. 2012 Mar;124(3):569-74. doi: 10.1016/j.ygyno.2011.10.022. Epub 2011 Oct 28. Gynecol Oncol. 2012. PMID: 22037316 Free PMC article. Clinical Trial.
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Leslie KK, et al. Among authors: lankes ha. Gynecol Oncol. 2012 Nov;127(2):345-50. doi: 10.1016/j.ygyno.2012.07.127. Epub 2012 Aug 7. Gynecol Oncol. 2012. PMID: 22885469 Free PMC article. Clinical Trial.
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. Coleman RL, et al. Among authors: lankes ha. Gynecol Oncol. 2012 Dec;127(3):538-43. doi: 10.1016/j.ygyno.2012.08.020. Epub 2012 Aug 23. Gynecol Oncol. 2012. PMID: 22922531 Free PMC article. Clinical Trial.
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Farley J, et al. Among authors: lankes ha. Lancet Oncol. 2013 Feb;14(2):134-40. doi: 10.1016/S1470-2045(12)70572-7. Epub 2012 Dec 21. Lancet Oncol. 2013. PMID: 23261356 Free PMC article. Clinical Trial.
A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM. Powell MA, et al. Among authors: lankes ha. Gynecol Oncol. 2014 Oct;135(1):38-43. doi: 10.1016/j.ygyno.2014.07.083. Epub 2014 Jul 11. Gynecol Oncol. 2014. PMID: 25019571 Free PMC article. Clinical Trial.
Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Zighelboim I, Ali S, Lankes HA, Backes F, Moore K, Mutch D, Robison K, Behbakht K, Waggoner S, Ghebre RG, Pearl M, Ramirez NC, Goodfellow P. Zighelboim I, et al. Among authors: lankes ha. Gynecol Oncol. 2015 Sep;138(3):614-9. doi: 10.1016/j.ygyno.2015.06.038. Epub 2015 Jul 3. Gynecol Oncol. 2015. PMID: 26144601 Free PMC article.
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Bender D, Sill MW, Lankes HA, Reyes HD, Darus CJ, Delmore JE, Rotmensch J, Gray HJ, Mannel RS, Schilder JM, Hunter MI, McCourt CK, Samuelson MI, Leslie KK. Bender D, et al. Among authors: lankes ha. Gynecol Oncol. 2015 Sep;138(3):507-12. doi: 10.1016/j.ygyno.2015.07.018. Epub 2015 Jul 15. Gynecol Oncol. 2015. PMID: 26186911 Free PMC article. Clinical Trial.
Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Eskander RN, Ali S, Dellinger T, Lankes HA, Randall LM, Ramirez NC, Monk BJ, Walker JL, Eisenhauer E, Hoang BH. Eskander RN, et al. Among authors: lankes ha. Int J Gynecol Cancer. 2016 Jan;26(1):125-32. doi: 10.1097/IGC.0000000000000563. Int J Gynecol Cancer. 2016. PMID: 26397159 Free PMC article. Clinical Trial.
67 results